Working... Menu

A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00162032
Recruitment Status : Completed
First Posted : September 13, 2005
Results First Posted : December 6, 2013
Last Update Posted : December 6, 2013
Information provided by (Responsible Party):
Lantheus Medical Imaging

Brief Summary:
Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.

Condition or disease Intervention/treatment Phase
Kawasaki Disease Drug: Sestamibi Phase 3

Detailed Description:
The purpose of this clinical research study is to determine how well CARDIOLITE® rest and stress myocardial (heart) imaging can define the pediatric Kawasaki disease (KD) population into high and low risk categories of developing cardiac (heart) events (complications) from 1 year through 3 years after image completion. The safety of CARDIOLITE® rest and stress heart imaging will also be studied.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 445 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of CARDIOLITE® Myocardial Perfusion Imaging in Pediatric Subjects With Kawasaki Disease
Study Start Date : August 2005
Actual Primary Completion Date : May 2010
Actual Study Completion Date : December 2010

Arm Intervention/treatment
Children (Ages 4-11)
Children 4-11 years of age, intervention Sestamibi
Drug: Sestamibi
Other Name: Cardiolite

Adolescents (Ages 12-16)
Adolescents 12-16 years of age, intervention Sestamibi
Drug: Sestamibi
Other Name: Cardiolite

Primary Outcome Measures :
  1. Kawasaki Disease Population at High and Low Risk of Developing Cardiac Events Though Three Years Follow-up. [ Time Frame: 3 years ]
    The proportion of all patients who experienced cardiac events among patients with abnormal (SSS >=4, high risk) and normal (SSS <4, low risk) Cardiolite MPI scans during the follow-up period. A log-rank statistic (2-sided, alpha = 0.05) was computed to compare cardiac event-free survival in the high risk and low risk groups. The cardiac event rate is the cumulative event rate based on a Kaplan-Meier estimate conditional on the SPECT MPI score result.

Secondary Outcome Measures :
  1. Concordance Will be Determined Between the Presence of Perfusion Abnormalities Detected on Sestamibi Images and the Classification of Ischemic Heart Disease. [ Time Frame: 3 year follow up ]
  2. In Addition, a Determination of the Safety of Sestamibi Will be Evaluated at the End of the Study Through Adverse and Serious Adverse Events Reported and Evaluating Vital Signs, ECGs, Physical Exams and Laboratory Tests for Each Subject. [ Time Frame: 3 year follow up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females between 4 and 16
  • Meet the epidemiological definition of Kawasaki Disease or have a diagnosis of incomplete KD, including evidence of coronary artery disease as determined by their physician.
  • Be able to exercise adequately to achieve 85% age predicted maximum heart rate

Exclusion Criteria:

  • Terminal illness where expected survival is < 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00162032

  Hide Study Locations
Layout table for location information
United States, Alaska
Local Institution
Anchorage, Alaska, United States, 99508
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States, 72202
United States, California
Local Institution
Los Angeles, California, United States, 90027
Local Institution
Orange, California, United States, 92868
Local Institution
San Diego, California, United States, 92123
United States, Colorado
Local Institution
Denver, Colorado, United States, 80218
United States, Connecticut
Local Institution
Hartford, Connecticut, United States, 06106
Local Institution
New Haven, Connecticut, United States, 06511
United States, Hawaii
Local Institution
Honolulu, Hawaii, United States, 96813
United States, Illinois
Local Institution
Chicago, Illinois, United States, 60614
Local Institution
Chicago, Illinois, United States, 60637
Local Institution
Park Ridge, Illinois, United States, 60068
United States, Indiana
Local Institution
Indianapolis, Indiana, United States, 46201
United States, Kentucky
Local Institution
Lexington, Kentucky, United States, 40536
United States, Massachusetts
Local Institution
Boston, Massachusetts, United States, 02111
United States, Nevada
Local Institution
Las Vegas, Nevada, United States, 89109
United States, New York
Local Institution
New Hyde Park, New York, United States, 11040
Local Institution
New York, New York, United States, 10032
United States, North Carolina
Local Institution
Durham, North Carolina, United States, 27710
Local Institution
Greenville, North Carolina, United States, 27858
United States, Ohio
Local Institution
Cincinnati, Ohio, United States, 45229
Local Institution
Cleveland, Ohio, United States, 44101
United States, Pennsylvania
Local Institution
Hershey, Pennsylvania, United States, 17033
Local Institution
Philadelphia, Pennsylvania, United States, 19107
Local Institution
Pittsburgh, Pennsylvania, United States, 15213
United States, Virginia
Local Institution
Charlottesville, Virginia, United States, 22906
United States, Washington
Local Institution
Seattle, Washington, United States, 98105
Local Institution
Spokane, Washington, United States, 99204
United States, Wisconsin
Local Institution
Milwaukee, Wisconsin, United States, 53203
Local Institution
Belo Horizonte, Brazil
Local Institution
Campinas, Brazil
Local Institution
Curitiba, Brazil
Local Institution
Rio de Janeiro, Brazil
Local Institution
Sao Paulo, Brazil
Canada, British Columbia
Local Institution
Vancouver, British Columbia, Canada
Canada, Nova Scotia
Local Institution
Halifax, Nova Scotia, Canada
Canada, Ontario
Local Institution
Toronto, Ontario, Canada
Canada, Quebec
Local Institution
Montreal, Quebec, Canada
Korea, Republic of
Local Institution
Daejeon, Korea, Republic of
Local Institution
Pusan, Korea, Republic of
Local Insitution
Seoul, Korea, Republic of
Local Institution
Suwon, Korea, Republic of
Local Institution
Wonju, Korea, Republic of
Local Institution
Quezon City, Philippines
Local Institution
Changhua, Taiwan
Local Institution
Kaohsiung, Taiwan
Local Institution
Taichung, Taiwan
Local Institution
Taipei, Taiwan
Local Institution
Bangkok, Thailand
Local Institution
Hatyai, Thailand
Sponsors and Collaborators
Lantheus Medical Imaging
Layout table for investigator information
Study Director: Qi Zhu, MD, Lantheus Medical Imaging

Layout table for additonal information
Responsible Party: Lantheus Medical Imaging Identifier: NCT00162032     History of Changes
Other Study ID Numbers: CARDIOLITE® 301
First Posted: September 13, 2005    Key Record Dates
Results First Posted: December 6, 2013
Last Update Posted: December 6, 2013
Last Verified: April 2012

Additional relevant MeSH terms:
Layout table for MeSH terms
Mucocutaneous Lymph Node Syndrome
Vascular Diseases
Cardiovascular Diseases
Lymphatic Diseases
Skin Diseases, Vascular
Skin Diseases
Technetium Tc 99m Sestamibi
Molecular Mechanisms of Pharmacological Action